IQ TALG Induction Working Group Webinar Series
February 19, 2021
Webinar
The IQ Translational and ADME Leadership Group (TALG) Induction Working Group (IWG) will hold a two-part webinar series based on its two recent publications:
- Perspectives from the Innovation and Quality Consortium Induction Working Group on Factors Impacting Clinical Drug-Drug Interactions Resulting from Induction: Focus on Cytochrome 3A Substrates (Drug Metabolism and Disposition, 2019)
- Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Guidelines on Model Fitting and Recommendations on Time Course for In Vitro Cytochrome P450 Induction Studies Including Impact on Drug Interaction Risk Assessment (Drug Metabolism and Disposition, 2021)
This public webinar series serves as an online platform to promote pre-competitive interaction and collaboration among industry-peers. We encourage you to share this with interested peers and colleagues. As a public series, IQ membership is not required for registration.
*Separate registration for each webinar is required.
Part I: 19 February 2021, 12:00-1:30 PM ET
Factors Impacting Magnitude of Clinical DDI Due to Induction: Focus on CYP3A Substrates
Speaker: Diane Ramsden, Associate Scientific Director in global DMPK, Takeda
This webinar will guide the audience through potential contributors to variability in clinical induction response, and highlight areas that may lead to improved extrapolation.
Part II: 25 February 2021, 12:00-1:00 PM ET
Time Course for In Vitro CYP Induction Studies: Impact on Drug Interaction Risk Assessment
Speaker: Simon Wong, Director, Pliant Therapeutics
This webinar will introduce the audience to model-fitting approaches and present recommendations related to the time-course for optimal in vitro induction and the impact on drug-drug interaction risk assessment.